114 related articles for article (PubMed ID: 21839068)
21. Cell-free circulating DNA: Diagnostic value in patients with renal cell cancer.
Hauser S; Zahalka T; Ellinger J; Fechner G; Heukamp LC; VON Ruecker A; Müller SC; Bastian PJ
Anticancer Res; 2010 Jul; 30(7):2785-9. PubMed ID: 20683013
[TBL] [Abstract][Full Text] [Related]
22. Levels of circulating cell-free nuclear and mitochondrial DNA in benign and malignant ovarian tumors.
Zachariah RR; Schmid S; Buerki N; Radpour R; Holzgreve W; Zhong X
Obstet Gynecol; 2008 Oct; 112(4):843-50. PubMed ID: 18827127
[TBL] [Abstract][Full Text] [Related]
23. Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma.
Battayani Z; Grob JJ; Xerri L; Noe C; Zarour H; Houvaeneghel G; Delpero JR; Birmbaum D; Hassoun J; Bonerandi JJ
Arch Dermatol; 1995 Apr; 131(4):443-7. PubMed ID: 7726587
[TBL] [Abstract][Full Text] [Related]
24. Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma.
Visús C; Andres R; Mayordomo JI; Martinez-Lorenzo MJ; Murillo L; Sáez-Gutiérrez B; Diestre C; Marcos I; Astier P; Godino J; Carapeto-Marquez de Prado FJ; Larrad L; Tres A
Melanoma Res; 2007 Apr; 17(2):83-9. PubMed ID: 17496783
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance and diagnostic value of protein S-100 and tyrosinase in patients with malignant melanoma.
Andrés R; Mayordomo JI; Visus C; Isla D; Godino J; Escudero P; Saenz A; Ortega E; Lastra R; Lambea J; Aguirre E; Elosegui L; Marcos I; Ruiz-Echarri M; Millastre E; Sáez-Gutierrez B; Asin L; Vidal MJ; Ferrer A; Giner A; Larrad L; Carapeto FJ; Tres A
Am J Clin Oncol; 2008 Aug; 31(4):335-9. PubMed ID: 18845991
[TBL] [Abstract][Full Text] [Related]
26. Assessment of circulating serum DNA integrity in colorectal cancer patients.
Yörüker EE; Özgür E; Keskin M; Dalay N; Holdenrieder S; Gezer U
Anticancer Res; 2015 Apr; 35(4):2435-40. PubMed ID: 25862911
[TBL] [Abstract][Full Text] [Related]
27. Serum ceruloplasmin in melanoma patients.
Ros-Bullón MR; Sánchez-Pedreño P; Martínez-Liarte JH
Anticancer Res; 2001; 21(1B):629-32. PubMed ID: 11299817
[TBL] [Abstract][Full Text] [Related]
28. Role of cell-free plasma DNA as a diagnostic marker for prostate cancer.
Allen D; Butt A; Cahill D; Wheeler M; Popert R; Swaminathan R
Ann N Y Acad Sci; 2004 Jun; 1022():76-80. PubMed ID: 15251943
[TBL] [Abstract][Full Text] [Related]
29. Serum sialic acid in malignant melanoma patients: an ROC curve analysis.
Ros-Bullón MR; Sánchez-Pedreño P; Martínez-Liarte JH
Anticancer Res; 1999; 19(4C):3619-22. PubMed ID: 10629661
[TBL] [Abstract][Full Text] [Related]
30. Circulating mitochondrial DNA in the serum of patients with testicular germ cell cancer as a novel noninvasive diagnostic biomarker.
Ellinger J; Albers P; Müller SC; von Ruecker A; Bastian PJ
BJU Int; 2009 Jul; 104(1):48-52. PubMed ID: 19154496
[TBL] [Abstract][Full Text] [Related]
31. Interleukin-6 and its surrogate C-reactive protein are useful serum markers for monitoring metastasized malignant melanoma.
Deichmann M; Benner A; Waldmann V; Bock M; Jäckel A; Näher H
J Exp Clin Cancer Res; 2000 Sep; 19(3):301-7. PubMed ID: 11144523
[TBL] [Abstract][Full Text] [Related]
32. Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors.
Proebstle TM; Jiang W; Högel J; Keilholz U; Weber L; Voit C
Br J Cancer; 2000 Jan; 82(1):118-23. PubMed ID: 10638977
[TBL] [Abstract][Full Text] [Related]
33. Detection of melanoma cells in peripheral blood using reverse transcription polymerase chain reaction assay for tyrosinase mRNA.
Jung FA; Buzaid AC; Woods KV; Ross M; Grimm EA
Cancer Surv; 1996; 26():251-65. PubMed ID: 8783578
[No Abstract] [Full Text] [Related]
34. Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients.
Huang ZH; Li LH; Hua D
Cancer Lett; 2006 Nov; 243(1):64-70. PubMed ID: 16412565
[TBL] [Abstract][Full Text] [Related]
35. Cell-free DNA in the blood as a solid tumor biomarker--a critical appraisal of the literature.
Jung K; Fleischhacker M; Rabien A
Clin Chim Acta; 2010 Nov; 411(21-22):1611-24. PubMed ID: 20688053
[TBL] [Abstract][Full Text] [Related]
36. Detection of tyrosinase mRNA by an optimised nested RT-PCR in the peripheral blood of patients with advanced malignant melanoma.
Glumac N; Hocevar M; Snoj M; Novakovic S
J Exp Clin Cancer Res; 2001 Dec; 20(4):529-36. PubMed ID: 11876547
[TBL] [Abstract][Full Text] [Related]
37. Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications.
Busser B; Lupo J; Sancey L; Mouret S; Faure P; Plumas J; Chaperot L; Leccia MT; Coll JL; Hurbin A; Hainaut P; Charles J
Biomed Res Int; 2017; 2017():5986129. PubMed ID: 28484715
[TBL] [Abstract][Full Text] [Related]
38. Circulating vascular endothelial growth factor in cutaneous malignant melanoma.
Pelletier F; Bermont L; Puzenat E; Blanc D; Cairey-Remonnay S; Mougin C; Laurent R; Humbert P; Aubin F
Br J Dermatol; 2005 Apr; 152(4):685-9. PubMed ID: 15840099
[TBL] [Abstract][Full Text] [Related]
39. A new standardized absolute quantitative RT-PCR method for detection of tyrosinase mRNAs in melanoma patients: technical and operative instructions.
Vendittelli F; Santonocito C; Paradisi A; Romitelli F; Concolino P; Silveri SL; Sisto T; Capizzi R; Catricalà C; Mulè A; Di Carlo A; Zuppi C; Capoluongo E
Clin Chim Acta; 2009 Nov; 409(1-2):100-5. PubMed ID: 19747905
[TBL] [Abstract][Full Text] [Related]
40. Alterations in CDKN2A locus as potential indicator of melanoma predisposition in relatives of non-familial melanoma cases.
Levanat S; Situm M; Crnić I; Marasović D; Puizina-Ivić N; Pokupcić N; Musani V; Komar A; Kubat M; Furac I; Karija-Vlahović M; Krizanac S
Croat Med J; 2003 Aug; 44(4):418-24. PubMed ID: 12950144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
